SALLuting a new biomarker in hepatocellular carcinoma

Journal Title: Annals of Hepatology - Year 2014, Vol 13, Issue 2

Abstract

Authors and Affiliations

Andrea L. Inghilesi, Fabio Marra

Keywords

Related Articles

Portal hypertension and acute liver failure as uncommon manifestations of primary amyloidosis

Hepatic involvement in primary amyloidosis is an infrequent challenge to the hepatologist. Although usually asymptomatic, amyloidosis may have unusual manifestations. Liver biopsy is an important diagnostic tool for this...

Hepatitis C and hepatocellular carcinoma

Chronic hepatitis C virus infection is a well-recognized risk factor for occurrence of hepatocellular carcinoma (HCC). In Europe, Oceania and America, chronic hepatitis C and alcoholic cirrhosis are the main risk factors...

Spontaneous HBsAg seroconversion after severe flare of chronic hepatitis B infection

The results of the acute exacerbations of hepatitis B virus are varied from silent to severe acute hepatitis. HBsAg seroconversion induced by either antiviral drugs or occurred spontaneously, as a targeted end point of H...

Evaluation of the C3435T polymorphism in the MDR1 gene in patients with hepatocellular carcinoma

Introduction. Considering the high prevalence of liver tumors and the impact on patient survival, a greater understanding of the biological behavior of those tumors if of great importance. The multidrug resistance gene (...

Download PDF file
  • EP ID EP78390
  • DOI -
  • Views 115
  • Downloads 0

How To Cite

Andrea L. Inghilesi, Fabio Marra (2014). SALLuting a new biomarker in hepatocellular carcinoma. Annals of Hepatology, 13(2), 305-307. https://europub.co.uk./articles/-A-78390